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Objective: Traditional recommendations for peripheral arterial disease (PAD) risk factor reduction include smoking
cessation, low-fat/low-salt diet, exercise, and optimal medical management of chronic disease. Little attention has been
paid to the role of dietary supplementation of specific nutrients in the prevention of PAD.
Methods: This cross-sectional study used the National Health and Nutrition Examination Survey (NHANES) to
determine specific nutrients that are associated with prevalent PAD in the United States (US) population. NHANES data
include nationwide sampling of the US population, using physical examination, questionnaire, and laboratory testing.
PAD status was defined by an ankle-brachial index (ABI) of <0.9. Nutritional information was collected by 24-hour
dietary recall using the US Department of Agriculture dietary collection instrument. Data were linked to a database of
foods and their nutrient composition. Univariate and multivariate logistic regression analyses were performed to evaluate
associations between specific nutrient intake and the presence of PAD. Multivariate models adjusted for the effects of age,
gender, hypertension, coronary vascular disease, diabetes, and smoking.
Results: NHANES data for 1999 to 2004 included 7203 lower extremity examinations, of which 422 individuals had
prevalent PAD (5.9%). Examinees with PAD had significantly higher rates of hypertension, coronary artery disease,
diabetes, and smoking than those without PAD. Univariate analysis revealed that consumption of all nutrients considered
were associated with lower odds of PAD, including antioxidants (vitamins A, C, and E), folate, other B vitamins (B6, B12),
fiber, and polyunsaturated and saturated fatty acids. After adjustment for traditional risk factors, nutrients associated
with reduced prevalence of PAD were vitamin A (odds ratio [OR], 0.79; P  .036), vitamin C (OR, 0.84; P < .001),
vitamin E (OR, 0.78; P  .011), vitamin B6 (OR, 0.71; P  .023), fiber (OR, 0.65; P < .001), folate (OR, 0.67; P 
.006), and -3 (-linolenic) fatty acid (OR, 0.79; P  .028).
Conclusions: Improved nutrition is associated with a reduced prevalence of PAD in the US population. Higher
consumption of specific nutrients, including antioxidants (vitamin A, C, and E), vitamin B6, fiber, folate, and -3 fatty
acids have a significant protective effect, irrespective of traditional cardiovascular risk factors. These findings suggest
specific dietary supplementation may afford additional protection, above traditional risk factor modification, for the
prevention of PAD. ( J Vasc Surg 2008;48:897-904.)Peripheral arterial disease (PAD) is a potentially life- or
limb-threatening condition affecting 5.9% of the United
States (US) population aged 40 years, roughly 16.5 mil-
lion Americans (present study). Prevention and treatment
of PAD has focused on modification of cardiovascular risk
factors, which include smoking, hypertension, diabetes,
and hyperlipidemia. Life-style modification includes pro-
grams for smoking cessation, graduated exercise regimens,
and dietary changes. Medical intervention involves the
treatment of chronic disease using cholesterol-lowering
agents (statins), and antiplatelet agents, and antihyperten-
sive medicines, including angiotensin-converting enzyme
inhibitors and -blockers.1 Despite these guidelines, pa-
tients with PAD are relatively under-treated with regard to
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General dietary interventions often call for a low-fat,
low-salt diet for secondary treatment of cardiovascular dis-
ease, but recommendations for consumption of specific
nutrients are often lacking. The World Health Organiza-
tion (WHO) Study Group3 proposed guidelines for the
prevention of cardiovascular disease include a diet low in
total fat (30% of calories) and saturated fat (10% of
calories), and devoid of trans-fatty (saturated) acids. Salt
intake should be reduced to 5 g/d (90 mmol/d). Con-
sumption of a broad range of fruits, vegetables, and grain
(400 g/d) is encouraged. However, no recommendation
could be made for intake of vitamins B, C, E, and folic acid
due to a paucity of clinical evidence.
We have conducted a population-based study to exam-
ine the association between consumption of certain nutri-
ents and the prevalence of PAD within the US population.
Data from the National Health and Nutritional Examina-
tion Survey (NHANES)4 from 1999 to 2004 was used to
gather information on the dietary habits in the United
States. Nutrients examined in this study had previous evi-
dence of protective effect in the literature and include
antioxidants (vitamins A, C, and E), folate and B vitamins,
polyunsaturated fatty acids (PUFA), and dietary fiber. As-
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were explored using univariate and multivariate models.
Adjustment for the presence of cardiovascular risk factors
was performed to determine which nutrients might have a
protective effect in addition to traditional risk factor mod-
ification.
METHODS
Data source. NHANES conducts series of cross-
sectional surveys among the civilian, noninstitutionalized
US population by using a complex, stratified, multistage,
probability-sampling design. Data for this study included
NHANES 1999 to 2000, 2001 to 2002, and 2003 to
2004. Extracted data files included demographic informa-
tion, the ankle-brachial index (ABI) examination, 24-hour
dietary recall interview (total nutrient intake), and disease
history. These data files were obtained from the NHANES
Website4 and combined to create a single data set.
Ankle-brachial index measurements. Detailed de-
scriptionof theABImeasurementprocedurecanbe foundonthe
NHANESWebsite.4 All study participants aged40 years were
invited to participate in the lower extremity examination. Exclu-
sion criteria included people weighing 400 pounds or with
bilateral amputation. Other reasons for nonparticipation in the
lower extremity examination included (1) casts, ulcers, dressings
or other conditions of the participant that interfered with the
testing, (2)participantcouldnotunderstandthe test instructions,
(3) participant became ill and the test could not be performed,
(4)anequipment failureoccurred, (5) theparticipant refused, (6)
the participant that came late or left early from themobile exam-
ination center and the lower extremity disease examcouldnot be
performed, or (7) some other reason.
Supine systolic pressure was measured twice in the arm
(brachial artery) and both ankles (posterior tibial or dorsalis
pedis arteries, or both). The ABI was calculated by dividing
the systolic blood pressure at the ankle by the mean systolic
blood pressure in the arm. The smallest of the left or right ABI
calculations was used for this study to maximize numbers of
prevalent peripheral arterial disease (PAD), defined as an ABI
0.9.5
Nutrition variables. The variables include vitamins A,
C, E, B6, B12, fiber, folate, total polyunsaturated fatty
acids, linoleic acid, -linolenic acid, and total saturated fatty
acids. These were collected from the NHANES 1999 to
2004 first day dietary interview examination files. Quanti-
tative dietary intake data was obtained for all subjects by
means of a 24-hour dietary recall interview using the
NHANES computer-assisted dietary data interview system.
The 24-hour dietary recall collected a list of all the foods
and beverages consumed within a 24-hour period, the time
of consumption and the name of the eating occasion,
detailed food descriptions and amounts of the reported
foods, where the food was obtained, and whether it was
eaten at home or not. The recall was then followed by a set
of health-related questions. The data were collected with
the US Department of Agriculture’s (USDA) dietary data
collection instrument, the Automated Multiple Pass
Method.These data were then coded and linked to a database of
foods and their nutrient composition. Calculations of total
daily nutrient intakes were derived from these data. Refer-
ence nutrient values were based on recommendations by
the US Department of Health and Human Services, the
USDA,6 and the Food and Nutrition Board, Institute of
Medicine, National Academies,7 which incorporates rec-
ommended daily allowances and adequate intakes and vary
for individual life stage groups. TheUSDAfive-step,multiple-
pass method of 24-hour dietary recall has been validated for
both men and women.8
Associated risk factors. Age, sex, and comorbidities
of hypertension, coronary artery disease (CAD), diabetes,
and smoking were examined concomitantly with all nutri-
ent variables. Age in years was used as a continuous variable.
Hypertension was defined as self-reported medical history
of hypertension or systolic blood pressure140mmHg or
diastolic blood pressure90 mmHg on physical examina-
tion. CAD was defined as self-reported medical history of
coronary artery disease, angina, or stroke. Status of diabetes
was defined as self-reported medical history of diabetes.
Smoking status was defined as positive for participants
consuming more than 100 cigarettes over a lifetime.
Statistical analysis. All statistical analyses were con-
ducted with SAS 9.1 software (SAS Institute Inc, Cary,
NC). Because of the NHANES complex probability sam-
pling of the US population, sample weights, stratification,
and clustering of the sampling design were incorporated
into all SAS survey procedures to ensure the correct estima-
tion of standard errors, confidence intervals, and P values. A
6-year sample weight was created according to the
NHANES analytic guidelines4 for the combined 1999 to
2004 data by assigning one-third of the 2-year weight for
2003 to 2004 if a participant was sampled in 2003 to 2004
and merging it with the 1999 to 2002 4-year weight for
those sampled in 1999 to 2002. The stratification and
clustering variables used in all analyses were SDMVSTRA
and SDMVPSU, respectively.
All nutrient variables were highly skewed and thus nor-
malized by log-transformation before statistical analysis. Pear-
son correlation coefficients between nutrient variables were
calculated. Descriptive statistics included two-sided Student t
tests and Wald 2 analysis, where appropriate. Univariate
analyses were conducted to determine crude associations be-
tween putative predictor variables and PAD. Multivariate lo-
gistic regression was used to examine the potential protective
effects of a nutrient on PAD prevalence, with adjustment for
known risk factors. Adjusted bivariate analysis, stratified by
quartiles of nutrient consumption levels, was used to deter-
mine a dose–response effect, with comparisons made to avail-
able governmental nutritional guidelines. Statistical signifi-
cance was set at P  .05 or odds ratios (OR) and 95%
confidence intervals (CI) that excluded 1.
RESULTS
Demographics. Results of the population characteris-
tics of the United States are summarized in Table I. This
study included 7203 lower extremity examination partici-
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prevalent PAD. Comparisons are made between partici-
pants with PAD (ABI0.90) and those without PAD (ABI
0.90). Participants with PADwere older than those with-
out (mean age, 67.6 vs. 55.0 years; P  .001). Gender
distribution between the two groups was not significantly
different, and reflected the gender distribution of the over-
all population.
Traditional cardiovascular risk factors were more preva-
lent in the groupwith PAD.This includes a greater prevalence
of hypertension (65.6%  3.22% vs 34.6%  1.87%; P 
.001), CAD (11.2%  1.67% vs 2.67%  0.29%; P  .001),
diabetes (21.1%  2.76% vs 8.6%  0.41%; P  .001), and
smoking (68.6 3.52% vs 53.3% 1.01%; P .001) in the
PAD group.
Total caloric intake was lower in the group with PAD
than in those without (mean, 1742 vs 2100 Kcals; P 
.001). Consumption of most nutrients assayed was also
significantly lower in the group with PAD. This includes a
lower consumption of antioxidants (vitamins A, C, and E),
folate and vitamins B6 and B12, fiber, and polyunsaturated
fatty acids (linoleic and -linolenic acid) and total saturated
fatty acids. This reflects generalized poor nutrition among
participants with PAD.
Bivariate and multivariate analyses. Results of the
Table I. Population characteristics by peripheral arterial
disease status, National Health and Nutrition
Examination Survey, 1999 to 2004 (N  7203)a
Characteristicb
PAD (ABI 0.90)
PcYes (n  422) No (n  6781)
Age, years 67.6  0.57 55.0  0.14 .001
Female sex, % 56.1  3.68 51.6  0.64 .266
Hypertension, % 65.6  3.22 34.6  1.87 .001
CAD, % 11.2  1.67 2.67  0.29 .001
Diabetes, % 21.1  2.76 8.6  0.41 .001
Smoking, % 68.6  3.52 53.3  1.01 .001
Obesity, % 18.6  2.11 18.5  1.02 .637
Body mass index,
kg/m2 28.9  0.42 28.2  0.09 .589
Nutrients
Total calories, Kcal 1742  44.3 2100  15.8 .001
Vitamin A, ug 567.2  37.0 616.7  10.0 .316
Vitamin C, mg 78.5  4.03 94.0  1.15 .007
Vitamin E, mg 5.80  0.25 7.15  0.08 .001
Vitamin B6, mg 1.64  0.05 1.84  0.01 .004
Vitamin B12, g 4.96  0.34 5.15  0.11 .736
Fiber, g 13.9  0.50 16.3  0.12 .001
Folate, g 338.0  10.9 393.4  2.83 .001
Total PUFA, g 13.8  0.45 16.9  0.14 .001
Linoleic acid, g 12.2  0.40 14.9  0.13 .001
-Linolenic acid, g 1.24  0.04 1.50  0.01 .001
Total saturated
fatty acids, g 22.7  0.73 25.9  0.20 .001
ABI, Ankle-brachial index; CAD, coronary artery disease; PAD, peripheral
arterial disease; PUFA, polyunsaturated fatty acid.
aSix-year weight variable used for two-sided t test and Wald 2 analyses.
bValues are percentages  standard error or mean  standard error.
cStatistical significance at P  .05.bivariate analyses are summarized in Table II. The odds ofPAD were generally lowered with increased consumption
of all nutrients. This reflects an association between im-
proved nutrition and lower odds of PAD. This association
reached statistical significance for all nutrients examined
except for vitamin A (OR, 0.85; P .051) and vitamin B12
(OR, 0.88; P  .174).
Multivariate analyses are summarized in Table II. Tra-
ditional cardiovascular risk factors were used as covariates in
the model, including age, gender, hypertension, CAD,
diabetes, and smoking. By using this adjustment, the po-
tential protective effect of nutrient consumption can be
determined, irrespective of the effect of traditional risk
factors. The point estimates (ORs) for all nutrients were
1, except for total saturated fat consumption. This implies
that consumption of these nutrients showed some trend
toward a protective effect. Nutrients which showed a sig-
nificant association towards reduced OR of PAD included
vitamin A (OR, 0.79; P .036), vitamin C (OR, 0.84; P
.001), vitamin E (OR, 0.78; P  .011), vitamin B6 (OR,
0.71; P  .023), fiber (OR, 0.65; P  .001), folate (OR,
0.67; P  .006) and -linolenic fatty acid (OR, 0.79; P 
.028).
Quartile analysis. Results of unadjusted bivariate
analyses, stratified by quartile of consumption, are summa-
rized in Table III. This stratification was performed to
determine whether a dose–response effect could be seen in
participants consuming larger quantities of certain nutri-
ents. Threshold values for recommended consumption are
listed to evaluate the quartiles meeting or exceeding these
limits.
Results of these analyses are similar to the multivariate
analyses. A dose–response relationship was seen, with
higher levels of vitamin C consumption conferring a lower
likelihood of PAD (25.3 to 60mg/d: OR, 0.65; P .046).
A significant protective effect was also seen in quartiles
meeting or exceeding the threshold values for vitamin E
(8.58 mg/d: OR, 0.60; P  .039), vitamin B6 (1.08 to
1.58 mg/d: OR, 0.47; P .002), fiber (13.3 to 19.4 g/d:
OR, 0.65; P  .036), and folate (344 to 492 g/d: OR,
0.66; P  .019).
DISCUSSION
There is mounting evidence from experimental and
clinical studies that diet can have a profound effect on the
process of atherosclerosis. Diet not only affects the levels of
circulating blood lipids but can also modulate the immune
and inflammatory processes present in the epithelium that
affects the development of atherosclerotic plaque.9 This has
led to a number of putative nutritional targets that may
afford protection or secondary intervention in patients with
PAD. However, many clinical studies have conflicting re-
sults with regard to specific nutrient supplementation.10
Dietetic guidelines are often tailored for overall cardiovas-
cular health and do not specifically focus on peripheral
arterial disease.11
Onemajor finding of this study is the association between
poor caloric intake and a higher risk of PAD.Amongpeople in
the United States without PAD, there is a general increase in
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including saturated and polyunsaturated fatty acids. People
with PAD had reported decreased total calorie and nutrient
intake and had a higher prevalence of comorbid conditions,
including hypertension, CAD, and diabetes. This trend to-
wards poor caloric intake in patients with PAD and critical
limb ischemia has been previously reported.12
In contrast, improved nutrition and freedom from
PAD has also been associated. The Edinburgh Artery study
evaluated the effect of dietary factors on ABI in a prospec-
tive trial of 1592 adults.13 This showed an association
between higher ABI and increased consumption of cereal
fiber, meat, alcohol, and vitamins C and E. Our study finds
a similar pattern of poor dietary habits and higher preva-
lence of PAD. Alarmingly, most Americans do not meet the
US Food and Drug Administration (FDA)–required intake
of most nutrients; this difference is more pronounced
among the population with PAD.However, the association
between nutrition and PAD can be confounded by other
coexistent medical conditions, such as age, diabetes, CAD,
and smoking. We conducted further analyses in attempt to
adjust for other coexisting medical conditions to indepen-
dently evaluate the effect of nutrition.
Antioxidants. Vitamin A (most commonly retinol) is
a fat-soluble antioxidant that is important in vision, bone
growth, and immune function. It is found in many yellow
and orange vegetables, as well as butter, eggs, and liver.
Vitamin C (ascorbic acid) is water-soluble antioxidant,
most commonly found in citrus fruit. It is a well known for
its role in scurvy prevention as well as its importance in
immune function and maintenance of the redox state.
Previous clinical studies have shown vitamin C levels are
reduced in PAD patients and correlates with reduced walk-
ing distance and systemic inflammation (C-reactive pro-
tein).14 However, not all clinical trials involving vitamin C
supplementation have shown positive effects on PAD.15
Vitamin E (tocopherol) is a membrane-bound antiox-
Table II. Unadjusted and adjusted bivariate logistic regre
Nutrientsb
Unadjusted analysis f
OR 95% CI
Vitamin A 0.85 0.73-1.00
Vitamin C 0.88 0.81-0.96
Vitamin E 0.66 0.56-0.78
Vitamin B6 0.68 0.55-0.83
Vitamin B12 0.88 0.73-1.06
Fiber 0.66 0.56-0.77
Folate 0.62 0.51-0.75
Total PUFA 0.68 0.59-0.80
Linoleic acid 0.70 0.61-0.81
-Linolenic acid 0.72 0.60-0.85
Total saturated fatty acids 0.76 0.65-0.90
CI, Confidence intervals; OR, odds ratio; PAD, peripheral arterial disease;
aModels adjusted for age, gender, hypertension, diabetes, and smoking. Six
bSee Table III for intake levels of the various nutrients.
cStatistical significance at P  .05.idant that has been linked to reduction in cellular damageseen in cardiovascular disease. It is found most commonly
in nuts, vegetable oils, and fish. Vitamin E supplementation
has long been used as preventative treatment for cardiovas-
cular disease. In the Rotterdam study,16 improved vitamin
E intake was correlated with a reduction in PAD and
increased ABI. However, in the large, randomized Heart
Outcomes Prevention Evaluation (HOPE) trial,17 dietary
supplementation with vitamin E showed no decrease in
cardiovascular events among patients with diabetes or vas-
cular disease.
We found that increased consumption of antioxidants,
vitamins A, C, and E, was associated with reduced odds of
PAD in unadjusted analyses (Table II). In multivariate
analyses (Table II), when the effect of traditional cardiovas-
cular risk factors is adjusted, the association between anti-
oxidant intake and lower odds of PAD is maintained. In
quartile analysis (Table III), the benefit of higher levels of
vitamin C consumption was seen in a dose–response rela-
tionship, lending some support to higher levels of vitamin
C supplementation. Additional benefit was also seen in the
highest quartile of vitamin E consumption (8.58 mg/d:
OR, 0.60; P  .039).
This strong association observed in the United States
population between improved antioxidant intake and re-
duced PAD disease should not be misinterpreted as a
cause-and-effect relationship. More definitive evidence for
antioxidant use will be provided by clinical trials, such as
Critical Leg Ischemia Prevention Study (CLIPS), evaluat-
ing both vitamin C and E supplementation.
Folate and other B vitamins. Hyperhomocysteinemia
is a known independent risk factor for the development of
PAD.18 About 30% of patients with PAD have hyperhomo-
cysteinemia, and their severity of disease is correlated with
plasma homocysteine levels.19 Folate supplementation has
been shown to reduce plasma homocysteine levels in PAD
patients,20 and the addition of vitamins B6 and B12 may
potentate this effect. In addition, many observational stud-
analysisa
D Adjusted analysis for PAD
Pc OR 95% CI Pc
0.051 0.79 0.63-0.99 0.036
0.002 0.84 0.76-0.92 0.001
0.001 0.78 0.65-0.94 0.011
0.001 0.71 0.53-0.95 0.023
0.174 0.94 0.72-1.21 0.626
0.001 0.65 0.53-0.79 0.001
0.001 0.67 0.52-0.88 0.006
0.001 0.83 0.68-1.01 0.061
0.001 0.85 0.70-1.03 0.091
0.001 0.79 0.65-0.98 0.028
0.001 1.07 0.84-1.36 0.596
, polyunsaturated fatty acid.
weight variable used for analysis.ssion
or PA
PUFA
-yearies have reported a strong relationship between B vitamin
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Nutrients Dietary Health Guidelinesb Dietary Reference Intake/dayc OR of PAD 95% CI Pd
Vitamin A, g
260 1.00
260-463 0.95 0.59-1.54 .839
464-756 700-900 700-900 0.67 0.40-1.13 .132
757 700-900 700-900 0.65 0.35-1.20 .167
Vitamin C, mg
25.3 1.00
25.3-60.0 0.65 0.42-0.99 .046
60.1-125.1 75-90 75-90 0.65 0.47-0.90 .009
125.2 0.51 0.34-0.75 .001
Vitamin E, mg
3.63 1.00
3.63-5.57 0.81 0.53-1.25 .337
5.58-8.57 0.83 0.58-1.20 .326
8.58 15 15 0.60 0.37-0.97 .039
Vitamin B6, mg
1.08 1.00
1.08-1.58 1.3-1.7 1.3 0.47 0.29-0.76 .002
1.59-2.33 0.72 0.49-1.04 .078
2.34 0.56 0.33-0.96 .034
Vitamin B12, g
2.18 1.00
2.18-3.85 2.4 2.4 0.98 0.62-1.55 .932
3.86-6.29 0.71 0.46-1.09 .118
6.30 0.99 0.59-1.65 .971
Fiber, g
8.67 1.00
8.67-13.2 0.87 0.62-1.22 .403
13.3-19.4 0.65 0.44-0.97 .036
19.5 28 25-38 0.51 0.33-0.79 .002
Folate, g
233 1.00
233-343 0.76 0.55-1.05 .098
344-492 400 400 0.66 0.47-0.93 .019
493 0.63 0.38-1.04 .070
Total PUFAs, g NA NA
8.94 1.00
8.94-14.2 0.77 0.50-1.18 .225
14.3-21.7 0.86 0.56-1.33 .496
21.8 0.72 0.47-1.11 .136
Linoleic acid, g
7.74 1.00
7.74-12.3 12-14 0.74 0.48-1.15 .225
12.4-19.0 12-14 12-17 0.87 0.57-1.34 .496
19.1 0.68 0.44-1.04 .136
-Linolenic acid
0.75 1.00
0.75-1.20 1.1-1.6 1.1-1.6 0.98 0.69-1.38 .893
1.21-1.88 1.1-1.6 1.1-1.6 0.95 0.63-1.44 .814
1.89 0.70 0.48-1.03 .068
Total saturated fatty acids, g Minimal
15.6 1.00
15.6-23.7 20 1.00 0.64-1.56 .998
23.8-35.1 1.24 0.80-1.92 .332
35.2 1.00 0.60-1.64 .986
CAD, Coronary artery disease; CI, confidence interval; OR, odds ratio; PAD, peripheral arterial disease; PUFA, polyunsaturated fatty acid.
aModels adjusted for age, sex, hypertension, CAD, diabetes, and smoking. Six-year weight variable used for analysis.
bUS Department of Health and Human Services, US Department of Agriculture; based on a 2000 calorie diet; ranges are female-male values.
cBased on criteria by Food and Nutrition Board, Institute of Medicine, National Academies, which incorporates Recommended Daily Allowances (RDAs) and
Adequate Intakes; ranges are females-male values and for individuals aged 40 years.
dStatistical significance at P  .05.
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consumption are predictors of PAD in men aged 50
years, independent of other cardiovascular risk factors.21
The Health Professionals Follow-up Study also observed a
relationship between folate and B6 consumption and PAD
risk.22 In fact, a meta-analysis suggested that lowering
homocysteine levels in patients with cardiovascular disease
by 3 mol/L would reduce the risk of cardiac events
by 16%.23
The results of randomized trials have not been as
encouraging, however. In the HOPE trial,17 high-risk car-
diovascular patients were randomized to treatment with
combination therapy (folate, vitamin B6, and B12) or pla-
cebo. Despite reduction in homocysteine levels, there was
no observed reduction in overall cardiovascular events. In
fact, in the Norwegian Vitamin Trial (NORVIT),24 supple-
mentation with B vitamins actually increased the risk of
cardiac events. It should be noted that these trials were
specifically designed to evaluate cardiac outcomes, and
PAD end points were not evaluated.
Our study evaluated the relationship to B-vitamin con-
sumption and prevalence (OR) of PAD. We found that
increased folate intake was associated with reduced odds of
PAD in both unadjusted (OR, 0.62; P  .001) and ad-
justed (OR, 0.67; P  .006) analyses. Vitamin B6 also
showed positive associations in the unadjusted (OR, 0.68;
P  .001) and adjusted models (OR, 0.71; P  .023). No
significant trends were observed for vitamin B12. Quartile
analysis showed consumption at FDA-recommended levels
of folate (344 to 492 g/d: OR, 0.66; P  .019) and
vitamin B6 (1.08 to 1.58 mg/d, OR, 0.47; P  .002)
conferred additional protective effect.
These results suggest that dietary intake of folate and
vitamin B6 may be beneficial in the prevention of PAD.
However, the discrepancy between the findings of observa-
tional studies and randomized trial evidence in the cardiac
literature should not be overlooked. Further trials evaluat-
ing the effect of B-vitamin supplementation on specific
peripheral vascular outcomes are forthcoming.
Fiber. There is considerable observational evidence
for the beneficial role of dietary fiber. The Edinburgh
Artery study13 found a positive association between cereal
fiber intake and increased ABI measurements. A similar
positive association between cereal fiber and increased ABI
was seen in theHealth Professional’s Follow-up Study.25 In
addition, there is some suggestion that increased fiber
consumption may exert anti-inflammatory effects. In a
study using the 1999 to 2000 NHANES data, a strong
association was seen between fiber intake and C-reactive
protein levels.26 Randomized trial evidence for fiber sup-
plementation and PAD risk reduction is lacking.
Our study shows a strong protective effect of fiber con-
sumption on PAD risk in both unadjusted (OR, 0.66; P 
.001) and adjusted analyses (OR, 0.65; P  .001). There is
some suggestion that higher levels of fiber intake have addi-
tional protective effect in quartile analysis (13.3 to 19.4 g/d:
OR, 0.65; P  .036). It should be noted that the highest
quartile of fiber consumption in the US population began at19.5 gm/d, a value that is well below those suggested by the
DietaryHealthGuideline (28 g/d) and theDietary Reference
Intake (25 to 38 g/d).
Overall, it is difficult to isolate the specific effect of fiber
supplementation. Food, such as cereal, that is high in fiber
is also high in other nutrients, such as folate and vitamin E.
With the use of the USDA Automated Multiple Pass
Method used in this study, the effect of fiber alone could be
evaluated in PAD risk reduction.
Dietary fat. Polyunsaturated fats (PUFA) can be clas-
sified as 	-3, commonly derived from fish oils, and 	-6,
which is found in olive oils and in the Mediterranean diet.
The primary role of PUFA in the reduction of cardiovascu-
lar risk is mainly due to an anti-inflammatory effect. Both
	-3 and 	-6 PUFAs participate in the arachidonic acid
pathway and alter the ratio of prostaglandin and leukotri-
ene production.27 This anti-inflammatory effect has been
experimentally shown to help stabilize atherosclerotic
plaque and promote plaque repair.28
Dietary consumption of 	-3 fatty acid was supported
by the FDA in 2006, when it released a qualified health
claim that	-3 PUFAsmay reduce the risk of coronary heart
disease. This statement was based on evidence from meta-
analyses that showed the use of fish and fish oil supplements
reduced cardiovascular events and overall mortality.29 The
protective effect seen in the Mediterranean diet is thought
to come from 	-6 PUFA, especially in the form of olive oil.
Olive oil has been shown to lower plasma cholesterol and
serum low-density lipoprotein cholesterol, as well as have
and anti-inflammatory effect.30
In our study we chose to represent 	-3 PUFA con-
sumption with -linolenic acid, and 	-6 PUFA with lino-
leic acid. In unadjusted population-level analysis, we found
people with PAD had a reduced consumption of PUFAs
(including -linolenic and linoleic acids) and saturated fatty
acids. This reflects a generally poor nutrition in participants
with PAD. In unadjusted analysis, both PUFAs (OR, 0.68;
P  .001) and saturated fatty acids (OR, 0.76; P  .001)
conferred a protective effect against PAD. This observed
protective effect of saturated fatty acids may be con-
founded with improved overall nutrition associated with
improved caloric intake. In adjusted analysis, however,
saturated fatty acid consumption did not show a protec-
tive effect (OR, 1.07; P  .596). Adjusted analyses did
show a protective effect of 	-3 fatty acid (-linolenic;
OR, 0.79; P  .028), whereas 	-6 fatty acid (linoleic)
did not (OR, 0.85; P  .091). No benefit was seen in
higher levels of consumption of fatty acids in quartile
analyses. These findings lend support to the FDA claim
that a diet low in saturated fats and high in PUFAs
(especially 	-3 fatty acids) may confer a protective effect
against CAD and PAD.
Limitations. The use of the NHANES data set has
allowed us to explore the relationship between the con-
sumption of specific nutrients and the prevalence of PAD
within the US population. By using survey data, we are able
JOURNAL OF VASCULAR SURGERY
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studies and extrapolate our findings to the dietary habits in
the entire population.
The use of this type of data is not without limitations,
however. Because the data are a cross-sectional observa-
tional representation, causality between nutrient consump-
tion and the development of PAD cannot be determined.
The data presented are also subject to the methodologic
constraints posed by the conduct of NHANES and are
themselves subject to selection bias because not all partici-
pants who were selected underwent the lower extremity
examination or dietary analysis. Furthermore, a 24-hour
dietary recall can be a restricted measure of overall nutrition
and is subject to inaccuracies and recall bias. Finally, be-
cause of the large number of participants in the NHANES
study, small differences in nutrient intake or small differ-
ences in ABI measurements can lead to statistical signifi-
cance. It is incumbent on the reader to determine their
relative clinical significance.
In our multivariate model, only traditional risk factors
for PAD, including age, gender, CAD, diabetes, and smok-
ing were included as covariates. This adjustment was done
to determine the effect of nutrient intake independent of
traditional cardiovascular risk factors. Certain variables
were excluded from these models because we believed this
would lead to over-adjustment and reduced discrimination.
These factors include total caloric intake, body mass index
(BMI), obesity, and race. Tables IV (online only) and V
(online only) evaluate the effect of these variables on the
model.
The prevalence of obesity and mean BMI is not statis-
tically different between participants with or without PAD
(Table I), so this factor was not included as a covariate. The
effect of obesity or BMI may be confounded by other
important factors, such as exercise, which are not well
coded in the NHANES data set. Racial and socioeconomic
effects were also not included in multivariate models (Ta-
bles IV, online only, and V, online only). The NHANES
survey purposefully under-samples racial minorities based
on their prevalence within the US population. We believe
that true disparities may exist in racial and socioeconomic
access to proper nutrition, and this may have an impact on
PAD. However, this must be considered in a separate study
designed to look for these differences.
Conclusive evidence for dietary supplementation in
PAD must come from randomized trial evidence. Our
findings suggest multiple nutrients must be supplemented to
achieve a balanced nutritional approach. In a recently pub-
lished small Spanish trial that used these methods,31 60 pa-
tients with PAD were randomly assigned to receive a supple-
ment containing PUFAs, and vitamins A, B6, D, and E. At 1
year, they were able to show significant improvements in
serologic markers, walking distance, and ABI measure-
ment. We believe in the validity of this approach and
encourage larger clinical trials to be performed in the
United States.CONCLUSIONS
Despite these limitations, we believe our data give
strong observational evidence to the role of nutrition in the
prevalence of PAD. We found that in adjusted models,
antioxidants (vitamins A, C, and E), B vitamins (folate and
B6), and fiber intake were associated with a protective effect
going beyond that explained by traditional cardiovascular
risk factors. In addition, a diet low in saturated fats and high
in 	-3 fatty acids may also confer a protective effect against
PAD. Among the 16.5 million Americans with PAD, our
study showed extremely poor dietary habits, with average
levels of nutritional intake far below the FDA suggested
dietary guidelines. This allows for considerable dietary im-
provement on a nationwide scale.
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Volume 48, Number 4 Lane et al 904.e1Table IV. (online only). Additional adjusted bivariate log
racea
Body mass index (kg/m2)
Nutrientsb OR of PAD 95% CI Pc
Vitamin A 0.76 0.59-0.98 0.032
Vitamin C 0.81 0.71-0.94 0.004
Vitamin E 0.81 0.58-1.13 0.209
Vitamin B6 0.70 0.47-1.04 0.075
Vitamin B12 0.96 0.74-1.25 0.757
Fiber 0.61 0.44-0.84 0.003
Folate 0.61 0.41-0.89 0.011
Total PUFA 0.84 0.60-1.17 0.304
Linoleic acid 0.85 0.61-1.18 0.331
-Linolenic acid 0.85 0.60-1.20 0.353
Total saturated fatty acids 0.95 0.66-1.35 0.759
CI, Confidence interval; OR, odds ratio; PAD, peripheral arterial disease; P
aAll models adjusted for age, gender, hypertension, diabetes, and smoking.
bSee Table III for intake levels of the various nutrients.
cStatistical significance at P  .05.
Table V. (online only). Additional adjusted bivariate log
Obesity (30 kg/m2)
Nutrientsb OR of PAD 95% CI Pc
Vitamin A 0.76 0.60-0.97 .024
Vitamin C 0.86 0.75-0.98 .026
Vitamin E 0.88 0.65-1.18 .379
Vitamin B6 0.74 0.53-1.03 .072
Vitamin B12 0.92 0.67-1.28 .631
Fiber 0.71 0.56-0.90 .005
Folate 0.66 0.49-0.88 .005
Total PUFA 0.87 0.67-1.13 .296
Linoleic acid 0.88 0.69-1.14 .340
-Linolenic acid 0.81 0.62-1.07 .134
Total saturated fatty acids 1.04 0.75-1.43 .833
CI, Confidence interval; OR, odds ratio; PAD, peripheral arterial disease; P
aAll models adjusted for age, gender, hypertension, diabetes, and smoking.
bSee Table III for intake levels of the various nutrients.
cStatistical significance at P .05.istic regression analysis for body mass index, kilocalories, and
Kilocalories Race
OR of PAD 95% CI Pc OR of PAD 95% CI Pc
0.75 0.56-1.00 0.053 0.76 0.59-0.97 .025
0.87 0.75-1.01 0.068 0.86 0.75-0.99 .030
0.92 0.64-1.34 0.675 0.88 0.66-1.18 .390
0.74 0.48-1.14 0.168 0.74 0.53-1.03 .077
0.97 0.65-1.44 0.873 0.92 0.66-1.28 .631
0.70 0.51-0.95 0.022 0.71 0.56-0.91 .007
0.63 0.44-0.91 0.014 0.66 0.49-0.89 .006
0.93 0.68-1.29 0.681 0.87 0.67-1.13 .299
0.95 0.70-1.30 0.767 0.89 0.69-1.14 .346
0.83 0.57-1.21 0.332 0.81 0.61-1.07 .144
1.37 0.83-2.28 0.218 1.03 0.75-1.42 .864
UFA, polyunsaturated fatty acids.
Six-year weight variable used for analysis.istic regression analysis for obesity, kilocalories, and racea
Kilocalories Race
OR of PAD 95% CI Pc OR of PAD 95% CI Pc
0.75 0.56-1.00 .053 0.76 0.59-0.97 .025
0.87 0.75-1.01 .068 0.86 0.75-0.99 .030
0.92 0.64-1.34 .675 0.88 0.66-1.18 .390
0.74 0.48-1.14 .168 0.74 0.53-1.03 .077
0.97 0.65-1.44 .873 0.92 0.66-1.28 .631
0.70 0.51-0.95 .022 0.71 0.56-0.91 .007
0.63 0.44-0.91 .014 0.66 0.49-0.89 .006
0.93 0.68-1.29 .681 0.87 0.67-1.13 .299
0.95 0.70-1.30 .767 0.89 0.69-1.14 .346
0.83 0.57-1.21 .332 0.81 0.61-1.07 .144
1.37 0.83-2.28 .218 1.03 0.75-1.42 .864
UFA, polyunsaturated fatty acids.
Six-year weight variable used for analysis.
